Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)-Reference-Cited by-同舟云学术

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)

Published:2012-07 Issue:7 Volume:23 Page:1919-1925
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Aranda E.,Manzano J.L.,Rivera F.,Galán M.,Valladares-Ayerbes M.,Pericay C.,Safont M.J.,Mendez M.J.,Irigoyen A.,Arrivi A.,Sastre J.,Díaz-Rubio E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/7/1919/518880/mdr560.pdf

Reference24 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Estimates of the cancer incidence and mortality in Europe in 2006;Ferlay;Ann Oncol,2007

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

4. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

5. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma;Ueda;Pancreas,2004

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials;Journal of Clinical Pharmacy and Therapeutics;2024-01

2. A meta-analysis and systematic review of randomized controlled trials in combination Gemcitabine with Erlotinib in the pancreatic cancer;2023-11-11

3. Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial;Clinical and Translational Radiation Oncology;2022-05

4. Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials;Expert Opinion on Investigational Drugs;2021-11-02

5. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2021-04